Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2018 | Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance

Keith Stewart, MB, ChB, of the Mayo Clinic, Rochester, MN, rounds up the Myeloma 2018 meeting, held in San Diego, CA, with Thomas Martin, MD, from UCSF School of Medicine, San Francisco, CA, and Florian Bassermann, MD, PhD, from the Technical University of Munich, Munich, Germany. Drug resistance was a key topic for the day, seeing presentations on resistance to proteasome inhibitors and IMiDs, and CD38 sensitivity. Immunotherapy, particularly CAR T-cell therapy, was another major focus for the day’s discussions, with mixed opinions on how this novel therapy should placed in therapy sequencing. All were in agreement though, that Myeloma 2018 was a huge success.